{"id":"NCT03665038","sponsor":"Sage Therapeutics","briefTitle":"A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)","officialTitle":"A Multicenter, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Brexanolone in the Treatment of Adolescent Female Subjects With Postpartum Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-07","primaryCompletion":"2021-01-08","completion":"2021-01-08","firstPosted":"2018-09-11","resultsPosted":"2022-08-11","lastUpdate":"2022-08-11"},"enrollment":28,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Post Partum Depression"],"interventions":[{"type":"DRUG","name":"Brexanolone","otherNames":[]}],"arms":[{"label":"Brexanolone","type":"EXPERIMENTAL"}],"summary":"This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From first dose of study drug up to end of follow-up period (up to Day 30)","effectByArm":[{"arm":"Double-Blind Phase: Placebo","deltaMin":4,"sd":null},{"arm":"Double-Blind Phase: Brexanolone","deltaMin":3,"sd":null},{"arm":"Open-Label Phase: Brexanolone","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.sagerx.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":8},"commonTop":["Infusion site pain","Nausea","Dizziness","Sedation","Headache"]}}